Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
A star-shaped DNA architecture, carrying five molecular beacon-like motifs, was constructed to display ten dengue envelope protein domain III (ED3)-targeting aptamers into a two-dimensional pattern precisely matching the spatial arrangement of ED3 clusters on the dengue (DENV) viral surface.
|
31767992 |
2020 |
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Purified fusion proteins induced serotype-specific neutralizing antibodies without cross-reaction against other serotypes and arboviruses after mouse immunization. hydrophobin-fused domain III of dengue envelope protein could be a promising strategy for easy and low-cost production of components of a tetravalent sub-unit vaccine against dengue.
|
31828570 |
2020 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The human immunodeficiency virus-1 (HIV-1) envelope protein gp120 is the major contributor to the pathogenesis of HIV-associated neurocognitive disorder (HAND).
|
31320730 |
2020 |
Dengue Fever
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, two highly conserved regions of dengue envelope protein were identified and an scFv was constructed against it.
|
30629625 |
2019 |
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Zika (ZIKV) and dengue (DENV) virus infections elicit a robust but cross-reactive antibody response against the viral envelope protein, while antibody responses against non-structural proteins (NS) are more virus specific.
|
30902827 |
2019 |
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we focused on the Dengue viral envelope protein (E); computational analyses ranging from extensive Molecular Dynamics (MD) simulations and energy-decomposition-based prediction of potentially immunoreactive regions identified putative epitope sequences.
|
31003530 |
2019 |
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, the consensus dengue virus envelope protein domain III fused to hydrophobin I of Trichoderma reesei was expressed in Pichia pastoris cultures and an in situ product removal by an ATPS using a non-ionic detergent, (Triton X-114) was performed.
|
30240632 |
2019 |
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated four types of recombinant envelope protein domain III (DV-rED III) derived from four dengue virus (DENV) serotypes for diagnostic potential in detecting IgM in acute phase (mainly 2-3 days after onset of fever).
|
31311082 |
2019 |
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
The virtual approach was based on generating different docking cycles of tetra, penta, hexa, and heptapeptide libraries by maximizing the discrimination between the amino acid motif in the ZIKV and dengue virus (DENV) envelope protein glycosylation site.
|
31533374 |
2019 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Structure-Guided Approach to Identify Potential Inhibitors of Large Envelope Protein to Prevent Hepatitis B Virus Infection.
|
31772697 |
2019 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, the aa 158 sequence determined attachment of the HBV envelope protein to the host cell, demonstrating the mechanism whereby HBV infection would create positive selection at this NTCP residue.
|
30541857 |
2019 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have developed a fully human, second-generation CAR directed against the envelope protein of hepatitis B virus on the surface of infected cells (S-CAR).
|
30852138 |
2019 |
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here we show that a viral membrane protein, the duck hepatitis B virus (DHBV) large envelope protein (DHBs L), produced by WG-CFPS, is phosphorylated upon translation at the same sites as DHBs L produced during DHBV infection of primary hepatocytes.
|
31850370 |
2019 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is the first report on the mechanisms of HBV envelope protein transport among the organelles, and the results provide important insights into the therapeutic control of HBV infection.
|
31118260 |
2019 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we modified synthetic lipid-based nanoparticles with targeting peptides derived from the hepatitis B virus large envelope protein (HBVpreS) to specifically target the sodium-taurocholate cotransporting polypeptide (NTCP; <i>SLC10A1</i>) on the sinusoidal membrane of hepatocytes.
|
31333191 |
2019 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
A novel T-cell epitope in the transmembrane region of the hepatitis B virus envelope protein responds upon dendritic cell expansion.
|
30415392 |
2019 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The high variation in envelope protein sequence among HCV isolates necessitates the inclusion of several isolates, spanning the major genotypes of HCV, in order to make strong conclusions concerning the cross-reactive neutralization potential of a given antibody.
|
30593643 |
2019 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Overall, statistically significant associations were found between HCV quasispecies diversity, selective pressure exerted on the HCV E2 envelope protein, and neutralizing activity of maternal immunoglobulins.
|
30365007 |
2019 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
NS2 also promotes HCV particle assembly by recruiting envelope protein 2 (E2) to the virus assembly sites located at the detergent-resistant membranes (DRM).
|
31597774 |
2019 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we evaluated two different semi-synthetic archaeosome formulations as an adjuvant to the E1/E2 HCV envelope protein in a murine model and compared antigen-specific humoral (levels of anti-E1/E2 IgG and HCV pseudoparticle neutralization) and cellular responses (numbers of antigen-specific cytokine-producing T cells) to those generated with adjuvant formulations composed of mimetics of commercial adjuvants including a squalene oil-in-water emulsion, aluminum hydroxide/monophosphoryl lipid A (MPLA) and liposome/MPLA/QS-21.
|
31816920 |
2019 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is a sensitive and robust method for future studies investigating B cell responses against the HCV Envelope protein.
|
31226262 |
2019 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
GNbAC1 is a monoclonal antibody directed against the envelope protein of a HERV with postulated involvement in MS.
|
30873219 |
2019 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, this analysis provides a neurobiological rationale for a recently completed clinical study in MS patients showing that antibody-mediated neutralization of pHERV-W ENV exerts neuroprotective effects.
|
31213545 |
2019 |
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Human endogenous retrovirus W envelope protein is expressed in the central nervous system of patients with MS, and sufficient amount of temelimab must reach the target.
|
31311668 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After NDV selectively infects tumor cells, the immune response induced by NDV's envelope protein and intracellular factors can effectively kill the tumor without affecting normal cells.
|
31531310 |
2019 |